Baqsimi® (glukagon näspulver): Farmakodynamik hos vuxna

Detailed Information

After administration of 3 mg NG in adult patients with type 1 diabetes, glucose levels began to rise as early as 5 minutes. By 10 minutes, the median glucose level was above 3.9 mmol/L (70 mg/dL). The mean maximum glucose increase was 7.8 mmol/L (140 mg/dL).¹

Glucose Raising Effect in Study 1

Both NG and IM glucagon elicited a similar BG-raising effect (Figure 1).²

Figure 1. Mean Blood Glucose Concentrations After Administration of NG and IM Glucagon²

Abbreviations: IM = intramuscular; IMG = intramuscular glucagon; NG = nasal glucagon (glucagon nasal powder).

Other Parameters

Gender and body weight had no clinically meaningful effect on the pharmacodynamics of NG.¹

Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacodynamics of NG.¹

References

1. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Suico J, Hovelmann U, Zhang S, et al. Nasal glucagon: a viable alternative to treat insulin-induced hypoglycemia in adults with type 1 diabetes. Talk presented at: Proceedings from the European Association for the Study of Diabetes; October 1-5, 2018; Berlin.

Glossary

BG = blood glucose

NG = nasal glucagon (glucagon nasal powder)

PD = pharmacodynamic